ArticleProceedings of the National Academy of Sciences of the United States of America2018
MRI demonstrates glutamine antagonist-mediated reversal of cerebral malaria pathology in mice.
Open access · bronzeAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 33 citations in OpenAlex.
- CD8+ T cells target cerebrovasculature in children with cerebral malaria.The Journal of clinical investigation · 2020Trial
- Bradykinin contributes to vasogenic edema in murine experimental cerebral malaria.The Journal of clinical investigation · 2026Article
- Safety, Tolerability, and Pharmacokinetics of 6-Diazo-5-Oxo-L-Norleucine in Malawian Adults With and Without Malaria: A Phase 1 Dose-Escalation Clinical Trial.The Journal of infectious diseases · 2026Article
- Recent insights into the roles and therapeutic potentials of GLS1 in inflammatory diseases.Journal of pharmaceutical analysis · 2025Review
- Contribution of Magnetic Resonance Imaging Studies to the Understanding of Cerebral Malaria Pathogenesis.Pathogens (Basel, Switzerland) · 2024Review
- DON in pediatric cerebral malaria, a phase I/IIA dose-escalation safety study: study protocol for a clinical trial.Trials · 2024Article
- Glutamine metabolism inhibition has dual immunomodulatory and antibacterial activities against Mycobacterium tuberculosis.Nature communications · 2023Article
- Pathogenetic mechanisms and treatment targets in cerebral malaria.Nature reviews. Neurology · 2023Review
- Distinct evolution of type I glutamine synthetase in Plasmodium and its species-specific requirement.Nature communications · 2023Article
- Article
- Pathogenesis of Cerebral Malaria: New Trends and Insights for Developing Adjunctive Therapies.Pathogens (Basel, Switzerland) · 2023Article
- Article
- Transcellular blood-brain barrier disruption in malaria-induced reversible brain edema.Life science alliance · 2022Article
- Pipecolic Acid, a Putative Mediator of the Encephalopathy of Cerebral Malaria and the Experimental Model of Cerebral Malaria.The Journal of infectious diseases · 2022Article
- Brain Magnetic Resonance Imaging Reveals Different Courses of Disease in Pediatric and Adult Cerebral Malaria.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Testing the impact of a single nucleotide polymorphism in a Plasmodium berghei ApiAP2 transcription factor on experimental cerebral malaria in mice.Scientific reports · 2020Article
- RTP4 inhibits IFN-I response and enhances experimental cerebral malaria and neuropathology.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Desperately Seeking Therapies for Cerebral Malaria.Journal of immunology (Baltimore, Md. : 1950) · 2020Review
- Glutamine Antagonist JHU-083 Normalizes Aberrant Hippocampal Glutaminase Activity and Improves Cognition in APOE4 Mice.Journal of Alzheimer's disease : JAD · 2020Article
- Glutamine antagonism attenuates physical and cognitive deficits in a model of MS.Neurology(R) neuroimmunology & neuroinflammation · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Brittany A RiggleLaboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852.ORCID 0000-0002-8297-8971
Sanhita SinharayCenter for Infectious Disease Imaging, Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, MD 20892.
William Schreiber-StainthorpCenter for Infectious Disease Imaging, Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, MD 20892.ORCID 0000-0002-7386-8754
Jeeva P MunasingheMagnetic Resonance Imaging Research Facility, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892.
Dragan MaricDivision of Intramural Research, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892.
Eva PrchalovaJohns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD 21205.
Barbara S SlusherJohns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD 21205.
Jonathan D PowellDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287.
Louis H MillerLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852 lmiller@niaid.nih.gov hammoudd@cc.nih.gov.
Susan K PierceLaboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852.
Dima A HammoudCenter for Infectious Disease Imaging, Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, MD 20892; lmiller@niaid.nih.gov hammoudd@cc.nih.gov.
National Institutes of Health · USJohns Hopkins University · USNational Institutes of Health Clinical Center · US
Funding
Mali International Center for Excellence in Research: Malaria immunologyZIAAI001064 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI PIERCE, SUSAN · 2009 to 2025
$25.1MTR&D Project 3P41EB028239 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI Jordan Green, JONATHAN P SCHNECK · 2019 to 2026
$11.5MCell-targeted glutamine antagonists as a novel therapy for lymphomaR01CA229451 · NCI · JOHNS HOPKINS UNIVERSITY · PI SLUSHER, BARBARA STAUCH · 2018 to 2022
$2.3MTargeting Tumor Metabolism as a Means of Enhancing ImmunotherapyR01CA226765 · NCI · JOHNS HOPKINS UNIVERSITY · PI LEONE, ROBERT DAVID · 2019 to 2023
$1.9MNovel brain penetrant metabolic inhibitors to treat MYC-driven medulloblastomaR01NS103927 · NINDS · JOHNS HOPKINS UNIVERSITY · PI RAABE, ERIC HUTTON, SLUSHER, BARBARA STAUCH · 2018 to 2021
$1.6MCore Research Services for Molecular Imaging and Imaging SciencesZICCL040013 · CLC · CLINICAL CENTER · PI FRANK, JOSEPH · 2009 to 2025
$0kNCI NIH HHS R01 CA226765NCI NIH HHS R01 CA229451NIBIB NIH HHS P41 EB028239NINDS NIH HHS R01 NS103927
Abstract
The deadliest complication of
Indexed as
AdultAnimalsAntimalarialsBiomarkersBlood-Brain BarrierBrainBrain EdemaChildDiazooxonorleucineDisease Models, AnimalDisease ProgressionFemaleGlutamineHumansMagnetic Resonance ImagingMalaria, CerebralAntimalarialsBiomarkersDiazooxonorleucineGlutaminecerebral malariaexperimental cerebral malariaglutamine antagonistMRIPlasmodium falciparum
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.